Streetbeat News

Price Targets

GTLB

Keybanc analyst Michael Turits maintains an Overweight rating on GitLab (NASDAQ:GTLB) and raises the price target from $50 to $60.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:31 am

GOOGL

Keybanc analyst Justin Patterson maintains an Overweight rating on Alphabet (NASDAQ:GOOGL) and raises the price target from $122 to $140.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:28 am

DBX

Keybanc analyst Thomas Blakey maintains an Overweight rating on Dropbox (NASDAQ:DBX) and raises the price target from $27 to $32.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:27 am

AEIS

Keybanc analyst Steve Barger maintains an Overweight rating on Advanced Energy Indus (NASDAQ:AEIS) and raises the price target from $125 to $130.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:26 am

COYA

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained an $11 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:22 am

ARGX

Raymond James analyst Danielle Brill maintains a Strong Buy rating on argenx (NASDAQ:ARGX) and raises the price target from $460 to $600.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:21 am

MUSA

Raymond James analyst Bobby Griffin maintains an Outperform rating on Murphy USA (NYSE:MUSA) and raises the price target from $315 to $350.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:19 am

MIRM

Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raised the price target from $81 to $82.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:16 am

ARQT

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $24.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:14 am

IVVD

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Invivyd (NASDAQ:IVVD) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:13 am